- Home
- WNEB vs XBIT Comparison
WNEB vs XBIT Comparison
Compare WNEB & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | XBIT |
|---|---|---|
| Founded | 1853 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.2M | 73.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WNEB | XBIT |
|---|---|---|
| Price | $12.73 | $2.42 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 52.9K | ★ 57.7K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | ★ 27.15 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $79,080,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | $19.51 | ★ N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $7.63 | $2.09 |
| 52 Week High | $13.95 | $4.67 |
Technical Indicators
Market Signals| Indicator | WNEB | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 47.14 |
| Support Level | $13.20 | $2.40 |
| Resistance Level | $13.51 | $2.55 |
| Average True Range (ATR) | 0.34 | 0.11 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 13.69 | 13.79 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.